Signs of Insufficiency Fractures Overlooked in a Patient Receiving Chronic Bisphosphonate Therapy

References

1. 1.↵
   1. Black DM,
   2. Schwartz AV,
   3. Ensrud KE,
   4. et al

   . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Black DM,
   2. Cummings SR,
   3. Karpf DB,
   4. et al

   . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Bone HG,
   2. Hosking D,
   3. Devogelaer JP,
   4. et al

   . Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189–99.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Goh SK,
   2. Yang KY,
   3. Koh JS,
   4. et al

   . Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349–53.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Kwek EB,
   2. Goh SK,
   3. Koh JS,
   4. Png MA,
   5. Howe TS

   . An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224–31.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Lenart BA,
   2. Neviaser AS,
   3. Lyman S,
   4. et al

   . Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353–62.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Black DM,
   2. Reid IR,
   3. Boonen S,
   4. et al

   . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243–54.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Das De S,
   2. Setiobudi T,
   3. Shen L,
   4. Das De S

   . A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 2010;92:679–86.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Neviaser AS,
   2. Lane JM,
   3. Lenart BA,
   4. Edobor-Osula F,
   5. Lorich DG

   . Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346–50.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Otto S,
    2. Abu-Id MH,
    3. Fedele S,
    4. et al

    . Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence–a multi-centre study. J Carniomaxillofac Surg 2011;39:272–7.

    OpenUrl
11. 11.↵
    1. Hagen JE,
    2. Miller AN,
    3. Ott SM,
    4. et al

    . Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. J Bone Joint Surg Am 2014;96:1905–9.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Saleh A,
    2. Hegde VV,
    3. Potty AG,
    4. Schneider R,
    5. Cornell CN,
    6. Lane JM

    . Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J 2012;8:103–10.

    OpenUrlPubMed